Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Testosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SHBG | P04278 | 5/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epitestosterone SCHEMBL14034478 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL617693 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL16305625 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13752937 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL11588466 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL2678780 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL12367194 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL21957465 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL22704809 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL17808819 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11972369-B2 | System and method for automated dosage calculation and patient treatment life cycle | THE SOTTOPELLE GROUP, LLC (US) | 2024-04-30 | — | — | US | claimed |
| US-20230259832-A1 | System and Method for Automated Dosage Calculation and Patient Treatment Life Cycle | THE SOTTOPELLE GROUP, LLC (US) | 2023-08-17 | — | — | US | claimed |
| US-11663529-B2 | System and method for automated dosage calculation and patient treatment life cycle | THE SOTTOPELLE GROUP, LLC (US) | 2023-05-30 | — | — | US | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| CN-118252932-A | Medicament for improving testicle aging and application thereof | 上海科技大学 | 2024-06-28 | — | — | CN | disclosed |
| US-11972369-B2 | System and method for automated dosage calculation and patient treatment life cycle | THE SOTTOPELLE GROUP, LLC (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC | 2024-04-25 | — | — | US | disclosed |
| US-11931452-B2 | Topical compositions containing rofecoxib and methods of making and using the same | JF PHARMA TECH LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-11798659-B2 | System and method for automated dosage calculation and patient treatment life cycle | The Sotto Pelle Group, LLC (US) | 2023-10-24 | — | — | US | disclosed |
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | VANDERBILT UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230259832-A1 | System and Method for Automated Dosage Calculation and Patient Treatment Life Cycle | THE SOTTOPELLE GROUP, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-1117357-A1 | METHODS AND APPARATUS FOR IMPROVED ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS | Zars, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018339-A1 | METHODS AND APPARATUS FOR IMPROVED ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS | ZARS, INC. (US) | 2000-04-06 | — | — | WO | disclosed |
| US-5968919-A | CONTAINING PENETRATION ENHANCER OF (HYDROCARBYL-SUBSTITUTED) 1,3-DIOXOLANE, 1,3-DIOXANE OR ACETAL | MACROCHEM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0929295-A4 | — | — | 1999-08-18 | — | — | EP | disclosed |
| CN-1225008-A | Combined estrogen-androgen-progestin oral contraceptive | UNIV WAKE FOREST (US) | 1999-08-04 | — | — | CN | disclosed |
| EP-0929295-A1 | COMBINED PHARMACEUTICAL ESTROGEN-ANDROGEN-PROGESTIN ORAL CONTRACEPTIVE | WAKE FOREST UNIVERSITY (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5716800-A | TREATING SKIN DISORDER OILY AREAS | LVMH RECHERCHE (FR) | 1998-02-10 | — | — | US | disclosed |
| WO-1998001115-A1 | COMBINED PHARMACEUTICAL ESTROGEN-ANDROGEN-PROGESTIN ORAL CONTRACEPTIVE | WAKE FOREST UNIVERSITY (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738004-B2 | Indomethacin analogs for the treatment of castrate-resistant prostate cancer | AKR1C3, AKR1C4, AKR1C1 | AR 18/4885LMNA 2546/4885CYP3A4 572/4885 |
| US-20240130980-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | COQ8A, ATP5ME, AGK | AR 952/4885LMNA 3710/4885CYP3A4 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.